Biosearch and Seegene Finalize Oligonucleotide Supply and BHQ®, CAL Fluor® and Quasar® Licensing Agreements
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Biosearch Technologies, Inc., announces that the company has licensed access to the BHQ®, CAL Fluor® and Quasar® patents to Seegene. In addition, Biosearch will manufacture both research and IVD grade oligonucleotides for Seegene. Based in Seoul, Korea with a subsidiary in Rockville, Maryland, Seegene develops molecular diagnostic products based on PCR and real-time PCR technology.
Seegene’s Magicplex and Anyplex systems developed based on Seegene’s proprietary DPO and READ technologies are being sold in Human IVD, applied and research markets.
“Seegene’s multiplex PCR technology, combined with Biosearch’s BHQ, CAL Fluor, Quasar IP and oligo manufacturing expertise are a powerful and innovative solution in multiplex molecular diagnostics on real time PCR platforms” said Marc Beal, Director of Corporate Development at Biosearch Technologies. “We look forward to working with Seegene as they commercialize their current Seeplex, Magicplex and Anyplex product lines in Europe, Asia and the U.S.”
Dr. Sang-Kil Lee, Seegene’s Director of Business Development comments, “We are pleased to have a good partner in Biosearch Technologies, who can supply us sophisticated and high quality oligonucleotide components. We believe Seegene’s real time PCR products will offer both companies a whole new business opportunity in the global market, delivering a powerful multiplicity, sensitivity and specificity over a wide range of applications such as sepsis and MDR-TB.”
Seegene’s Magicplex and Anyplex systems developed based on Seegene’s proprietary DPO and READ technologies are being sold in Human IVD, applied and research markets.
“Seegene’s multiplex PCR technology, combined with Biosearch’s BHQ, CAL Fluor, Quasar IP and oligo manufacturing expertise are a powerful and innovative solution in multiplex molecular diagnostics on real time PCR platforms” said Marc Beal, Director of Corporate Development at Biosearch Technologies. “We look forward to working with Seegene as they commercialize their current Seeplex, Magicplex and Anyplex product lines in Europe, Asia and the U.S.”
Dr. Sang-Kil Lee, Seegene’s Director of Business Development comments, “We are pleased to have a good partner in Biosearch Technologies, who can supply us sophisticated and high quality oligonucleotide components. We believe Seegene’s real time PCR products will offer both companies a whole new business opportunity in the global market, delivering a powerful multiplicity, sensitivity and specificity over a wide range of applications such as sepsis and MDR-TB.”
